MX2021005169A - Metodos y composiciones para el tratamiento de carcinoma hepatocelular usando antisentido. - Google Patents

Metodos y composiciones para el tratamiento de carcinoma hepatocelular usando antisentido.

Info

Publication number
MX2021005169A
MX2021005169A MX2021005169A MX2021005169A MX2021005169A MX 2021005169 A MX2021005169 A MX 2021005169A MX 2021005169 A MX2021005169 A MX 2021005169A MX 2021005169 A MX2021005169 A MX 2021005169A MX 2021005169 A MX2021005169 A MX 2021005169A
Authority
MX
Mexico
Prior art keywords
compositions
methods
antisense
hepatocellular carcinoma
irradiated
Prior art date
Application number
MX2021005169A
Other languages
English (en)
Inventor
Douglas Craig Hooper
David Andrews
Emily Bongiomo
Original Assignee
Univ Jefferson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Jefferson filed Critical Univ Jefferson
Publication of MX2021005169A publication Critical patent/MX2021005169A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/126—Immunoprotecting barriers, e.g. jackets, diffusion chambers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/844—Liver
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense

Abstract

La presente descripción se refiere a composiciones y métodos para tratar cánceres de hígado, especialmente carcinoma hepatocelular, usando ácidos nucleicos antisentido (AS) dirigidos contra el receptor del factor de crecimiento 1 similar a la insulina (IGF-1R). El AS se puede administrar a los pacientes de forma sistémica o se puede usar para producir una vacuna de células cancerosas autólogas. En modalidades, los AS se proveen en una cámara de biodifusión irradiada implantable que comprende células tumorales y una cantidad eficaz de AS. Las cámaras se irradian e implantan en el abdomen de los sujetos y estimulan una respuesta inmunológica que ataca a los tumores distalmente. Las composiciones y métodos descritos en este documento pueden usarse para tratar muchos tipos diferentes de cáncer de hígado.
MX2021005169A 2018-11-02 2019-10-31 Metodos y composiciones para el tratamiento de carcinoma hepatocelular usando antisentido. MX2021005169A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862755064P 2018-11-02 2018-11-02
PCT/US2019/059017 WO2020092682A1 (en) 2018-11-02 2019-10-31 Methods and compositions for treating hepatocellular carcinoma using antisense

Publications (1)

Publication Number Publication Date
MX2021005169A true MX2021005169A (es) 2021-08-05

Family

ID=70463969

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021005169A MX2021005169A (es) 2018-11-02 2019-10-31 Metodos y composiciones para el tratamiento de carcinoma hepatocelular usando antisentido.

Country Status (7)

Country Link
US (1) US20210403918A1 (es)
EP (1) EP3873498A4 (es)
JP (1) JP2022512896A (es)
AU (1) AU2019374061A1 (es)
CA (1) CA3118424A1 (es)
MX (1) MX2021005169A (es)
WO (1) WO2020092682A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020007844A (es) * 2018-01-24 2021-01-20 Univ Jefferson Camara de biodifusion.
WO2024077130A1 (en) * 2022-10-05 2024-04-11 Thomas Jefferson University Methods and compositions for treating bladder cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050043233A1 (en) * 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
JP6957035B2 (ja) * 2015-04-10 2021-11-02 トーマス・ジェファーソン・ユニバーシティ 対象への移植用の免疫原性拡散チャンバおよびその調製方法
WO2018165528A1 (en) * 2017-03-09 2018-09-13 Thomas Jefferson University Methods and compositions for treating cancers using antisense

Also Published As

Publication number Publication date
CA3118424A1 (en) 2020-05-07
JP2022512896A (ja) 2022-02-07
WO2020092682A9 (en) 2020-06-04
US20210403918A1 (en) 2021-12-30
EP3873498A1 (en) 2021-09-08
AU2019374061A1 (en) 2021-06-03
EP3873498A4 (en) 2022-11-30
WO2020092682A1 (en) 2020-05-07

Similar Documents

Publication Publication Date Title
MX2019010725A (es) Metodos y composiciones para tratar canceres usando antisentido.
Tsang et al. Improving immunological tumor microenvironment using electro-hyperthermia followed by dendritic cell immunotherapy
RU2017126610A (ru) Терапевтические композиции и способы против злокачественных опухолей с молекулами рнки, направленными против hsp47
Dev et al. Electrochemotherapy—a novel method of cancer treatment
JP2019534308A5 (es)
Keller et al. Oncolytic viruses—immunotherapeutics on the rise
WO2019055880A3 (en) Method of administration and treatment
CA2253632A1 (en) Compositions and methods for treating cancers and pathogen infections using antigen-presenting cells loaded with rna
JP2019504105A5 (es)
MX2021005169A (es) Metodos y composiciones para el tratamiento de carcinoma hepatocelular usando antisentido.
JP2015516496A5 (es)
EP4023233A3 (en) Optimized oncolytic viruses and uses thereof
PH12020500665A1 (en) Pladienolide derivatives as spliceosome targeting agents for treating cancer
EA201100626A1 (ru) Лечение рака с помощью ионизирующего облучения и иммуноцитокинов
EP1723963A3 (en) Hapten-conjugated tumour cells
MX2021005168A (es) Metodos y composiciones para el tratamiento de cancer de mama usando antisentido.
MX2021011760A (es) Metodos para el tratamiento de canceres usando antisentido.
Bae et al. Enhanced anti-cancer effect of 5-fluorouracil loaded into thermo-responsive conjugated linoleic acid-incorporated poloxamer hydrogel on metastatic colon cancer models
WO2019241641A3 (en) Cancer treatment methods
MX2021001288A (es) Vacunacion con microvesiculas derivadas de celulas tumorales para tratamiento de cancer.
Safonova et al. Correction of damaging effects of cisplatin-containing polychemotherapy on the intestinal epithelium with Tussilago farfara L. Polysaccharides.
Tong et al. Inhibiting human breast cancer cells (mcf-7) with alternating micro-current at intermediate frequency (acif) in vitro and in vivo
WO2021127556A8 (en) Methods for treating cancer comprising low dose radiation
Levitsky et al. Allogeneic anti-PTK7 CAR-T cells for the treatment of solid tumors
CN106456687A (zh) 包含辣木叶提取物的放射线联合处理用组合物及利用其的治疗方法